Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics

被引:102
作者
Blum, D
Hourez, R
Galas, MC
Popoli, P
Schiffmann, SN
机构
[1] Free Univ Brussels, Neurophysiol Lab, B-1070 Brussels, Belgium
[2] CHU Brugmann, Dept Neurol, Brussels, Belgium
[3] Inst Super Sanita, Dept Pharmacol, Rome, Italy
关键词
D O I
10.1016/S1474-4422(03)00411-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Huntington's disease (HD) is a devastating hereditary neurodegenerative disorder, the progression of which cannot be prevented by any neuroprotective approach, despite major advances in the understanding of its pathogenesis. The study of several animal models of the disease has led to the discovery of both loss-of-normal and gain-of-toxic functions of the mutated huntingtin protein and the elucidation of the mechanisms that underlie the formation of huntingtin aggregates and nuclear inclusions. Moreover, these models also provide good evidence of a role for excitotoxicity and mitochondrial metabolic impairments in striatal neuronal death. Adenosine has neuroprotective potential in both acute and chronic neurological disorders such as stroke or Parkinson's disease. Here we review experimental data on the role of A(1) and A(2A) adenosine receptors in HD that warrant further investigation of the beneficial effects of A(1) agonists and A(2A) antagonists in animal models of HD. Future pharmacological analysis of adenosine receptors could justify the use of A(1) agonists and A(2A) antagonists for the treatment of HD in clinical trials.
引用
收藏
页码:366 / 374
页数:9
相关论文
共 142 条
[1]   PREFERENTIAL LOSS OF STRIATO-EXTERNAL PALLIDAL PROJECTION NEURONS IN PRESYMPTOMATIC HUNTINGTONS-DISEASE [J].
ALBIN, RL ;
REINER, A ;
ANDERSON, KD ;
DURE, LS ;
HANDELIN, B ;
BALFOUR, R ;
WHETSELL, WO ;
PENNEY, JB ;
YOUNG, AB .
ANNALS OF NEUROLOGY, 1992, 31 (04) :425-430
[2]   Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases [J].
Alexi, T ;
Borlongan, CV ;
Faull, RLM ;
Williams, CE ;
Clark, RG ;
Gluckman, PD ;
Hughes, PE .
PROGRESS IN NEUROBIOLOGY, 2000, 60 (05) :409-470
[3]   CHARACTERIZATION OF THE ADENOSINE RECEPTORS MEDIATING HYPOTHERMIA IN THE CONSCIOUS MOUSE [J].
ANDERSON, R ;
SHEEHAN, MJ ;
STRONG, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (04) :1386-1390
[4]   Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - An in situ hybridization study [J].
Arzberger, T ;
Krampfl, K ;
Leimgruber, S ;
Weindl, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (04) :440-454
[5]   Motor and cognitive improvements in patients with Huntington's disease after neural transplantation [J].
Bachoud-Lévi, A ;
Rémy, P ;
Nguyen, JP ;
Brugières, P ;
Lefaucheur, JP ;
Bourdet, C ;
Baudic, S ;
Gaura, V ;
Maison, P ;
Haddad, B ;
Boissé, MF ;
Grandmougin, T ;
Jény, R ;
Bartolomeo, P ;
Dalla Barba, G ;
Degos, JD ;
Lisovoski, F ;
Ergis, AM ;
Pailhous, E ;
Cesaro, P ;
Hantraye, P ;
Peschanski, M .
LANCET, 2000, 356 (9246) :1975-1979
[6]   Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide [J].
Barth, A ;
Newell, DW ;
Nguyen, LB ;
Winn, HR ;
Wender, R ;
Meno, JR ;
Janigro, D .
BRAIN RESEARCH, 1997, 762 (1-2) :79-88
[7]   Energetics in the pathogenesis of neurodegenerative diseases [J].
Beal, MF .
TRENDS IN NEUROSCIENCES, 2000, 23 (07) :298-304
[8]  
BEAL MF, 1993, J NEUROSCI, V13, P4181
[9]   Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation [J].
Behrens, P. F. ;
Franz, P. ;
Woodman, B. ;
Lindenberg, K. S. ;
Landwehrmeyer, G. B. .
BRAIN, 2002, 125 :1908-1922
[10]   Adenosine A(1) receptor agonists as clinically viable agents for treatment of ischemic brain disorders [J].
Bischofberger, N ;
Jacobson, KA ;
vonLubitz, DKJE .
NEUROPROTECTIVE AGENTS - THIRD INTERNATIONAL CONFERENCE, 1997, 825 :23-29